Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost

References

• Rosenberg DM, Cook SF, Lanza LL. Health care, treatment patterns and cost of services for patients infected with chronic hepatitis C virus in a large insured New England population. J Viral Hepat 2000;7:361-7
   PubMed Web of Science ®Google Scholar
• Poret AW, Ozminkowski RJ, Goetzel R, et al. Cost burden of illness for hepatitis C patients with employer-sponsored health insurance. Dis Manag 2002;5:95-107
   Google Scholar
• Su J, Brook RA, Kleinman NL, et al. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology (Baltimore, MD) 2010;52:436-42
   PubMed Web of Science ®Google Scholar
• Davis KL, Mitra D, Medjedovic J, et al. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol 2011;45:e17-24
   PubMed Web of Science ®Google Scholar
• McCombs JS, Yuan Y, Shin J, et al. Economic burden associated with patients diagnosed with hepatitis C. Clin Therapeut 2011;33:1268-80
   PubMed Web of Science ®Google Scholar
• McAdam-Marx C, McGarry LJ, Hane CA, et al. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. JMCP 2011;17:531-46
   PubMed Web of Science ®Google Scholar
• Tandon N, Reddy KR, Lefebvre P, et al. Direct and indirect cost burden of chronic hepatitis c infection in privately-insured patients, stratified by liver disease severity. Value Health 2013;16:A6
   Google Scholar
• Razavi H, Elkhoury AC, Elbasha E, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology (Baltimore, MD) 2013;57:2164-70
   PubMed Web of Science ®Google Scholar
• Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014;160:293-300
   PubMed Web of Science ®Google Scholar
• Blatt LM, Mutchnick MG, Tong MJ, et al. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat 2000;7:196-202
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55
   PubMed Web of Science ®Google Scholar
• Akiyama MJ, Piotrowski JI, Roytman MM, et al. New triple therapy for chronic hepatitis C: real life clinical experience in a community setting. Hawaii J Med Public Health 2013;72(9 Suppl 4):6-13
   Google Scholar
• Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (Baltimore, MD) 2009;49:1335-74
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Berg T, Moeller B, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 2009;16:75-90
   PubMed Web of Science ®Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28
   PubMed Web of Science ®Google Scholar
• Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Olysio (simeprevir) for the treatment of chronic hepatitis C in combination antiviral treatment. http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/ucm377234.htm. Accessed July 2014
   Google Scholar
• U.S. Food and Drug Administration. Approval of Sovaldi (sofosbuvir) tablets for the treatment of chronic hepatitis C. http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/ucm377234.htm. Accessed July 2014
   Google Scholar
• AASLD/IDSA/IAS–USA. Recommendations for testing, managing, and treating Hepatitis C. http://www.hcvguidelines.org/full-report-view. Accessed July 2014
   Google Scholar
• McCombs J, Matsuda T, Tonnu-Mihara I, et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. JAMA Intern Med 2013;90007:1-8
   Google Scholar
• Manos MM, Darbinian J, Rubin J, et al. The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting. JMCP 2013;19:438-47
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Sherker AH. Therapy for hepatitis C–the costs of success. N Engl J Med 2014;370:1552-3
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention. Surveillance for Viral Hepatitis – United States. http://www.cdc.gov/hepatitis/Statistics/2011Surveillance/Commentary.htm. Accessed October 2013
   Google Scholar
• McCombs JS, Shin J, Hines P, et al. Impact of drug therapy duration in patients with hepatitis C. Am J Pharm Benefits 2012;4:19-27
   Google Scholar
• Ong JP, Collantes R, Pitts A, et al. High rates of uninsured among HCV-positive individuals. J Clin Gastroenterol 2005;39:826-30
   PubMed Web of Science ®Google Scholar